Today: 22 May 2026
Browse Category

NASDAQ:KLIC 20 November 2025 - 6 February 2026

Kulicke & Soffa stock price today: KLIC steadies premarket after 19% earnings jump, Needham lifts target

Kulicke & Soffa stock price today: KLIC steadies premarket after 19% earnings jump, Needham lifts target

Kulicke & Soffa shares rose 0.4% to $66.66 in premarket trading Friday after a 19.3% surge Thursday, following upbeat Q2 revenue guidance of around $230 million. Fiscal Q1 net revenue reached $199.6 million, with utilization rates topping 80% in general semiconductors. Needham raised its price target to $70. The company filed its latest 10-Q on Thursday.
6 February 2026
··
Kulicke & Soffa (KLIC) Jumps 11% After Q4 2025 Earnings Beat and Upbeat 2026 Guidance

Kulicke & Soffa (KLIC) Jumps 11% After Q4 2025 Earnings Beat and Upbeat 2026 Guidance

KLIC shares jumped 11% to around $39.23 Thursday after Kulicke & Soffa posted better-than-expected Q4 earnings and raised its outlook for early fiscal 2026. Volume neared 900,000 shares by early afternoon. Q4 revenue reached $177.6 million, down 2% year over year but up 20% sequentially. The move follows a 12% after-hours surge Wednesday after the company beat Wall Street estimates.
20 November 2025

Stock Market Today

  • Q1 Earnings Review: Azenta Falls; West Pharmaceutical Leads Drug Development Services Stocks
    May 21, 2026, 9:31 PM EDT. Drug development inputs and services stocks, essential for pharmaceutical research and manufacturing, reported mixed Q1 results. Azenta (NASDAQ:AZTA), specializing in biological sample management, posted disappointing results with $144.8 million revenue, missing estimates and the weakest among peers, causing its share price to drop 23.4% to $17.65. Conversely, West Pharmaceutical Services (NYSE:WST), maker of specialized packaging and delivery devices, delivered a strong quarter with $844.9 million revenue, beating estimates by 8.4%. Overall, the sector's revenues beat consensus by 1.6%, despite an average 2.5% share price decline post-earnings. Tailwinds include growth in biologics and gene therapies, while headwinds feature pricing pressure and regulatory risks.

Latest articles

OpenAI Shares Hype Returns, Still No Ticker in Sight

OpenAI Shares Hype Returns, Still No Ticker in Sight

22 May 2026
OpenAI is preparing to confidentially file for a U.S. IPO, aiming to go public as early as September, sources told Reuters. The move follows a court win against Elon Musk, removing a key legal obstacle. Private-market share prices for OpenAI ranged from $658.94 to $732.38 this month, but no official public price exists. Ordinary investors still cannot buy OpenAI stock on public exchanges.
Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

22 May 2026
Estée Lauder and Spain’s Puig ended merger talks that would have created a $40 billion beauty group. Estée Lauder shares rose about 10% in after-hours trading, closing the regular session at $78.91. The company said it will focus on its turnaround plan and continue reviewing possible acquisitions or divestitures.
WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

22 May 2026
WhiteFiber shares jumped 22.2% to $29.55 after announcing a five-year AI compute contract worth over $160 million for a Paris-region deployment using NVIDIA GPU systems. Google Finance showed the stock rising further after hours. The project is backed by planned financing and 12 months of customer prepayments, but funding and execution remain pending. Service is expected to start in July, subject to equipment delivery and acceptance.
Go toTop